Last reviewed · How we verify
dexamethasone intraocular suspension, 9%
Dexamethasone is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.
Dexamethasone is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors. Used for Inflammation and pain following ocular surgery, Uveitis and other intraocular inflammatory conditions, Macular edema.
At a glance
| Generic name | dexamethasone intraocular suspension, 9% |
|---|---|
| Also known as | Dexycu |
| Sponsor | SR Cornea Consultants |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Dexamethasone reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene production, and suppressing immune cell infiltration and cytokine release. The intraocular suspension formulation delivers the drug directly to ocular tissues, providing sustained local anti-inflammatory effects while minimizing systemic exposure.
Approved indications
- Inflammation and pain following ocular surgery
- Uveitis and other intraocular inflammatory conditions
- Macular edema
Common side effects
- Elevated intraocular pressure
- Cataract formation
- Conjunctival hyperemia
- Eye irritation or discomfort
Key clinical trials
- Effect of Intraoperative Dexamethasone on Post-op Dry Eye (PHASE4)
- Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery (PHASE4)
- DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: